Valeant Pharmaceuticals International, Inc. Form 4 January 04, 2016

January 04, 20	510										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION							OMB APPROVAL				
Washington, D.C. 20549								OMB Number:	3235-0287		
Check this if no longe	r		~ - ~		~			Expires:	January 31, 2005		
subject to Section 16 Form 4 or	STATE	STATEMENT OF CHANGES IN BENEFICIAL OWNERS SECURITIES							Estimated a burden hou response	average Irs per	
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type Ro	esponses)										
MELAS KYRIAZI THEO Symbol			er Name and Ticker or Trading t Pharmaceuticals				5. Relationship of Reporting Person(s) to Issuer				
				national, Inc. [VRX]				(Check all applicable)			
(Last)(First)(Middle)3. Date of (Month/Da2150 ST. ELZEAR BLVD. WEST12/31/20				•				_X_Director10% Owner Officer (give titleOther (specify below) below)			
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
LAVAL, A8 H7L 4A8								Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	ecuri	ties Ac	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	ecurity (Month/Day/Year) Execution Date, if		3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or				SecuritiesHBeneficially(OwnedIFollowing(ReportedTransaction(s)	1	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common				Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Stock, no par value	12/31/2015			А	245 <u>(1)</u>	А	\$0	222,137	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

-	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Titl Amou Under Securi (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
MELAS KYRIAZI THEO 2150 ST. ELZEAR BLVD. WEST LAVAL, A8 H7L 4A8	Х						
Signatures							
by: Nicholas Zanoni for Theo Melas-Kyriazi	01/04/2016						
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Quarterly grant of Restricted Share Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.